Skip to Content

New quality of life data with immune-based treatment of metastatic renal cell carcinoma

Even in a first-line setting, where patient’s aims are usually unbalanced towards better antitumor activity and efficacy, QoL remains an important endpoint to pursue. In this MEDtalk Camilo Porta, Italy, presents new Quality of Life data from ESMO 2021.

Camillo Porta

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top